Tompkins Financial Corp Sells 3,495 Shares of Pfizer Inc. (NYSE:PFE)

Tompkins Financial Corp trimmed its position in Pfizer Inc. (NYSE:PFE) by 7.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,483 shares of the biopharmaceutical company’s stock after selling 3,495 shares during the period. Tompkins Financial Corp’s holdings in Pfizer were worth $1,172,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $315,000. GSA Capital Partners LLP bought a new position in shares of Pfizer during the first quarter valued at $439,000. Duality Advisers LP purchased a new position in shares of Pfizer in the 1st quarter worth about $1,009,000. Clifford Capital Partners LLC boosted its stake in Pfizer by 29.3% in the 1st quarter. Clifford Capital Partners LLC now owns 442,593 shares of the biopharmaceutical company’s stock worth $12,282,000 after purchasing an additional 100,210 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Pfizer during the 1st quarter valued at about $40,712,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PFE shares. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.32 during trading hours on Friday, hitting $26.72. The company’s stock had a trading volume of 55,951,315 shares, compared to its average volume of 37,583,031. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The business has a 50 day moving average price of $28.89 and a two-hundred day moving average price of $28.63. The company has a market cap of $151.42 billion, a PE ratio of 36.12, a PEG ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.